Literature DB >> 20872983

FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.

Lei Wang1, Wei-lai Xu, Hai-tao Meng, Wen-bin Qian, Wen-yuan Mai, Hong-yan Tong, Li-ping Mao, Yin Tong, Jie-jing Qian, Yin-jun Lou, Zhi-mei Chen, Yun-gui Wang, Jie Jin.   

Abstract

Mutations of fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) exon 12 genes are the most common abnormalities in adult acute myeloid leukemia (AML) with normal cytogenetics. To assess the prognostic impact of the two gene mutations in Chinese AML patients, we used multiplex polymerase chain reaction (PCR) and capillary electrophoresis to screen 76 AML patients with normal cytogenetics for mutations in FLT3 internal tandem duplication (FLT3/ITD) and exon 12 of the NPM1 gene. FLT3/ITD mutation was detected in 15 (19.7%) of 76 subjects, and NPM1 mutation in 20 (26.3%) subjects. Seven (9.2%) cases were positive for both FLT3/ITD and NPM1 mutations. Significantly more FLT3/ITD aberration was detected in subjects with French-American-British (FAB) M1 (42.8%). NPM1 mutation was frequently detected in subjects with M5 (47.1%) and infrequently in subjects with M2 (11.1%). FLT3 and NPM1 mutations were significantly associated with a higher white blood cell count in peripheral blood and a lower CD34 antigen expression, but not age, sex, or platelet count. Statistical analysis revealed that the FLT3/ITD-positive group had a lower complete remission (CR) rate (53.3% vs. 83.6%). Survival analysis showed that the FLT3/ITD-positive/NPM1 mutation-negative group had worse overall survival (OS) and relapse-free survival (RFS). The FLT3/ITD-positive/NPM1 mutation-positive group showed a trend towards favorable survival compared with the FLT3/ITD-positive/NPM1 mutation-negative group (P=0.069). Our results indicate that the FLT3/ITD mutation might be a prognostic factor for an unfavorable outcome in Chinese AML subjects with normal cytogenetics, while NPM1 mutation may be a favorable prognostic factor for OS and RFS in the presence of FLT3/ITD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872983      PMCID: PMC2950237          DOI: 10.1631/jzus.B1000052

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  30 in total

1.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

Authors:  Louise M Kelly; Qing Liu; Jeffrey L Kutok; Ifor R Williams; Christina L Boulton; D Gary Gilliland
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.

Authors:  Qin Huang; Wengang Chen; Karl K Gaal; Marilyn L Slovak; Anthony Stein; Lawrence M Weiss
Journal:  Br J Haematol       Date:  2008-05-09       Impact factor: 6.998

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

Authors:  F Hayakawa; M Towatari; H Kiyoi; M Tanimoto; T Kitamura; H Saito; T Naoe
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

5.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.

Authors:  Hitoshi Kiyoi; Ryuzo Ohno; Ryuzo Ueda; Hidehiko Saito; Tomoki Naoe
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

6.  Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.

Authors:  Rui Zheng; Alan D Friedman; Mark Levis; Li Li; Edward G Weir; Donald Small
Journal:  Blood       Date:  2003-10-30       Impact factor: 22.113

7.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Authors:  Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Maria Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

8.  Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Authors:  K-F Tse; J Allebach; M Levis; B D Smith; F D Bohmer; D Small
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

9.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Authors:  Stefan Fröhling; Richard F Schlenk; Jochen Breitruck; Axel Benner; Sylvia Kreitmeier; Karen Tobis; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.

Authors:  Rui Zheng; Alan D Friedman; Donald Small
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

View more
  7 in total

1.  Acute monocytic leukaemia with t(11; 12) (p15; q13) chromosomal changes: A case report and literature review.

Authors:  Jiasheng Hu; Xiuli Hong; Zhe Li; Quanyi Lu
Journal:  Oncol Lett       Date:  2015-07-20       Impact factor: 2.967

2.  Combined Expression of CD34 and FLT3-Internal Tandem Duplication Mutation Predicts Poor Response to Treatment in Acute Myeloid Leukemia.

Authors:  Mona S Abdellateif; Amira B Kassem; Yomna M El-Meligui
Journal:  Int J Gen Med       Date:  2020-10-16

3.  FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients.

Authors:  Ikhwan Rinaldi; Melva Louisa; Resti Mulya Sari; Elly Arwanih
Journal:  Onco Targets Ther       Date:  2021-02-26       Impact factor: 4.147

4.  Prognostic Impact of Nucleophosmin 1 (NPM1) Gene Mutations in Egyptian Acute Myeloid Leukemia Patients.

Authors:  Magda Zidan; Howyda Shaaban; Doaa El Ghannam
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

5.  FLT3-ITD, NPM1, and DNMT3A Gene Mutations and Risk Factors in Normal Karyotype Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients in Upper Northern Thailand

Authors:  Piyanan Mevatee; Adisak Tantiworawit; Patrinee Traisathit; Chaniporn Puaninta; Umnat Mevatee; Sirinda Angsuchawan; Kanokkan Bumroongkit
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

6.  The Association of FLT3-ITD Gene Mutation with Bone Marrow Blast Cell Count, CD34, Cyclin D1, Bcl-xL and hENT1 Expression in Acute Myeloid Leukemia Patients.

Authors:  Paulus Budiono Notopuro; Jusak Nugraha; Budi Utomo; Harianto Notopuro
Journal:  Iran J Pathol       Date:  2020-07-16

7.  Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.

Authors:  Yahia Moualla; Faten Moassass; Bassel Al-Halbi; Walid Al-Achkar; Michael Georgeos; Haissam Yazigi; Atieh Khamis
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.